{
  "docId": "019de071-d756-7568-8588-410684bab010",
  "docSlug": "c18c99fc10f671fc397f8a743cdc0ce4",
  "documentTitle": "Aeglea BioTherapeutics | Results Presentation Deck | 23 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 23,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 24,
  "notes": "The slide uses a clear comparison table to demonstrate safety outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-d756-7568-8588-410684bab010/14",
  "deckHref": "/decks/019de071-d756-7568-8588-410684bab010",
  "deckJsonHref": "/decks/019de071-d756-7568-8588-410684bab010.json",
  "deckAnchorHref": "/decks/019de071-d756-7568-8588-410684bab010#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.085,
        "w": 0.884,
        "x": 0.058,
        "y": 0.732
      },
      "kind": "callout",
      "text": "Pegzilarginase was Well-Tolerated with No Discontinuations Due to Adverse Events",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e559bf3e-a6e3-43a1-a65c-3b946a7d11a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.014,
        "w": 0.473,
        "x": 0.037,
        "y": 0.898
      },
      "kind": "source-note",
      "text": "* TEAE: Treatment-Emergent Adverse Event; ‡ SAE: Serious Adverse Event; ◊ Adverse Event of Interest",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "457e5fea-e006-4f29-bbe0-c1889bf06669",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.498,
        "w": 0.65,
        "x": 0.175,
        "y": 0.218
      },
      "kind": "table",
      "text": "Comparison of TEAE, SAE, and other safety metrics between Pegzilarginase and Placebo.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aef4deb8-c52d-4e22-88c9-467a35100f96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.305,
        "x": 0.068,
        "y": 0.045
      },
      "kind": "title",
      "text": "PEACE Safety Profile",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab3a5d3d-3cff-4ea1-afa2-cba4da2bc558",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 5,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "81d36eb9-c56a-4571-9f51-feb9c7f6295f",
      "evidence": "Presents Pegzilarginase's benefits in managing arginine levels and improving patient outcomes.",
      "position": 1,
      "objective": "Demonstrates how Pegzilarginase meets the need for effective arginine reduction",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}